 reuters    california governor jerry brown on monday signed state legislation requiring drug companies to report certain price hikes for prescription medicines in a move that could set a model for other states to follow  the law  which aims to provide more transparency around pharmaceutical and biotech company pricing methods for their medicines  requires drug manufacturers to give a  day notice if prices are raised more than  percent over a two year period  the law also requires health plans and insurers to file annual reports outlining how drug costs affect healthcare premiums in california   californians have a right to know why their medication costs are out of control  especially when pharmaceutical profits are soaring   brown  a democrat  said in a statement on his website announcing the new legislation  the bill has been opposed by drugmakers  who argue that wholesale price increases do not reflect the actual prices paid for medicines after discounts and rebates  biotechnology innovation organization  bio   the leading biotech industry trade group  issued a statement condemning the bill and arguing that it would not serve its intended purpose   this law will neither provide meaningful information to patients nor lower prescription drug costs   the group said  adding that the law  seriously jeopardizes the future of california s leadership in this innovative industry   california is home to hundreds of biotechnology companies  pharmaceutical companies have so far dodged stricter federal oversight despite growing public and political outrage over pricing practices for both branded and some generic medicines  but states  struggling to cover rising healthcare costs  have been addressing the issue rather than wait for federal help  at least  bills on pharmaceutical pricing and payment have been introduced this year in  states  according to the national conference of state legislatures  a new maryland law takes aims at egregious price hikes on generic versions of older off patent drugs that are supposed to be far cheaper than the original branded medicines after some companies took massive increases on generic drugs not facing competition from other distributors  amid the furor some drugmakers  including allergan plc and abbvie inc  have voluntarily pledged one annual price increase of under  percent on branded prescription medicines  it had been common industry practice to raise prices twice a year  often by double digit percentages  however  even annual price hikes of  percent over a two year period would put a company in the crosshairs of the new california legislation  